Akari Therapeutics Plc (AKTX): Operating Cash Flow
-$10.57M
Year ended 2025-12-31
-$10.76M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$10.57M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$12.55M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$16.43M | n/m | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | -$21.50M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$18.85M | n/m | 2023-05-01, From 2021-01-01 |
| 2020-12-31 | -$16.95M | n/m | 2023-05-01, From 2020-01-01 |
| 2019-12-31 | -$12.92M | n/m | 2022-05-16, From 2019-01-01 |
| 2018-12-31 | -$22.77M | n/m | 2021-04-21, From 2018-01-01 |
| 2017-12-31 | -$31.60M | n/m | 2020-03-31, From 2017-01-01 |
| 2016-12-31 | -$24.62M | n/m | 2019-04-23, From 2016-01-01 |
| 2015-12-31 | -$4.97M | n/m | 2018-07-18, From 2015-01-01 |
| 2014-12-31 | -$1.48M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$5.45M | n/m | 2015-02-11, From 2013-01-01 |
| 2012-12-31 | -$2.13M | n/m | 2015-02-11, From 2012-01-01 |
| 2011-12-31 | -$1.01M | n/m | 2014-03-24, From 2011-01-01 |
| 2010-12-31 | -$366.0K | n/a | 2013-04-19, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | -$10.57M | n/m |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | -$29.76M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | -$17.63M | n/m |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | -$31.32M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | -$30.97M | n/m |
| NextCure, Inc. (NXTC) | 2025-12-31 | -$49.61M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
Compare AKTX, ATOS, VTGN, VRCA side by side · Screen every company in Pharmaceutical Preparations ↗